MPH Nexora announces strategic rebrand to Jianai

April 30, 2026

MPH Nexora Pty Ltd today announced a strategic rebrand to Jianai — a new brand identity that reflects the company's evolved global vision and its deepening commitment to life sciences innovation for the benefit of all humanity.

The name Jian Ai is drawn from philosophy, originating in 5th century BC China, and translates as 'universal, impartial love for all humanity' — the principle of caring for all people equally, regardless of origin, class, or circumstance. Pronounced 'Jee-en Eye', the name bridges East and West, carrying profound cultural resonance across international audiences.

The rebrand reflects the company's growth from an Australian AI platform into a genuinely global infrastructure company — with institutional partnerships spanning Australia, the United Kingdom, Hong Kong, and mainland China. The Jianai brand will be adopted across all forward-facing activities, digital presence, and new institutional engagements, with the primary domain transitioning to jianai.health.

The company's existing legal entity and trading operations under MPH Nexora will continue to honour all current contracts and agreements during the transition period.

"Jianai is not just a name — it is a statement of purpose," said Nigel Blair, Founder and CEO. "We are building an AI infrastructure platform that serves all of humanity — not just the well-resourced, not just the well-connected, but every researcher, every clinician, and every patient whose life could be changed by better science. Jian Ai captures that commitment in a way that resonates across cultures, across continents, and across generations."

The Jianai rebrand will be formally unveiled at the company's upcoming institutional events in April and May 2026, including a signing ceremony with the University of Hong Kong at the Asia Summit on Global Health in Hong Kong.

About Jianai
Jianai is an AI infrastructure platform for the global life sciences sector. Integrating research synthesis, regulatory automation, IP management, clinical trial preparation, and commercialisation enablement into a single secure architecture. Currently in beta with a diverse and growing group of life sciences users spanning research institutes, universities, and industry.

Media enquiries:


Level 11, 655 Elizabeth Street, Melbourne VIC 3000